Weill Cornell Medical College Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Latest from Weill Cornell Medical College Sandra & Edward Meyer Cancer Center


Dr. Ruan on Treatment Considerations for Relapsed/Refractory MCL

November 30, 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

October 01, 2020

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

From the Ophthalmologist’s Eye: Managing Ocular Toxicities With Belantamab Mafodotin in Myeloma

September 25, 2020

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.